236 related articles for article (PubMed ID: 36413492)
1. Approach to the Patient With Hypothalamic Obesity.
Shoemaker AH; Tamaroff J
J Clin Endocrinol Metab; 2023 Apr; 108(5):1236-1242. PubMed ID: 36413492
[TBL] [Abstract][Full Text] [Related]
2. Management of Hypothalamic Obesity.
Müller HL
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):533-552. PubMed ID: 32741487
[TBL] [Abstract][Full Text] [Related]
3. Interventions for the Treatment of Craniopharyngioma-Related Hypothalamic Obesity: A Systematic Review.
Ni W; Shi X
World Neurosurg; 2018 Oct; 118():e59-e71. PubMed ID: 29945001
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology and Individualized Treatment of Hypothalamic Obesity Following Craniopharyngioma and Other Suprasellar Tumors: A Systematic Review.
van Iersel L; Brokke KE; Adan RAH; Bulthuis LCM; van den Akker ELT; van Santen HM
Endocr Rev; 2019 Feb; 40(1):193-235. PubMed ID: 30247642
[TBL] [Abstract][Full Text] [Related]
5. Acquired hypothalamic obesity: A clinical overview and update.
Roth CL; McCormack SE
Diabetes Obes Metab; 2024 Apr; 26 Suppl 2():34-45. PubMed ID: 38450938
[TBL] [Abstract][Full Text] [Related]
6. Effects of T3 treatment on brown adipose tissue and energy expenditure in a patient with craniopharyngioma and hypothalamic obesity.
van Santen HM; Schouten-Meeteren AY; Serlie M; Meijneke RW; van Trotsenburg AS; Verberne H; Holleman F; Fliers E
J Pediatr Endocrinol Metab; 2015 Jan; 28(1-2):53-7. PubMed ID: 25514327
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Hypothalamic Obesity in Patients With Adult-Onset Craniopharyngioma: A Consecutive Series of 120 Cases.
Wu W; Sun Q; Zhu X; Xiang B; Zhang Q; Miao Q; Wang Y; Li Y; Ye H
Front Endocrinol (Lausanne); 2021; 12():694213. PubMed ID: 34394000
[TBL] [Abstract][Full Text] [Related]
8. Postoperative hypothalamic damage predicts postoperative weight gain in patients with adult-onset craniopharyngioma.
Wu J; Fu J; Huang ZJ; Xie SH; Tang B; Wu X; Tong ZG; Wu BW; Pan CB; Yang YQ; Ding H; Li SY; Qi JL; Hong T
Obesity (Silver Spring); 2022 Jul; 30(7):1357-1369. PubMed ID: 35707874
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon.
Roth CL; Zenno A
Front Endocrinol (Lausanne); 2023; 14():1256514. PubMed ID: 37780616
[TBL] [Abstract][Full Text] [Related]
10. Gastric bypass surgery for treatment of hypothalamic obesity after craniopharyngioma therapy.
Inge TH; Pfluger P; Zeller M; Rose SR; Burget L; Sundararajan S; Daniels SR; Tschöp MH
Nat Clin Pract Endocrinol Metab; 2007 Aug; 3(8):606-9. PubMed ID: 17643131
[TBL] [Abstract][Full Text] [Related]
11. Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity.
Roth CL; Eslamy H; Werny D; Elfers C; Shaffer ML; Pihoker C; Ojemann J; Dobyns WB
Obesity (Silver Spring); 2015 Jun; 23(6):1226-33. PubMed ID: 25884561
[TBL] [Abstract][Full Text] [Related]
12. Hypothalamic obesity in children.
Bereket A; Kiess W; Lustig RH; Muller HL; Goldstone AP; Weiss R; Yavuz Y; Hochberg Z
Obes Rev; 2012 Sep; 13(9):780-98. PubMed ID: 22577758
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Acquired Hypothalamic Obesity: Now and the Future.
Dimitri P
Front Endocrinol (Lausanne); 2022; 13():846880. PubMed ID: 35464063
[TBL] [Abstract][Full Text] [Related]
14. Outcome after bariatric surgery in two adolescents with hypothalamic obesity following treatment of craniopharyngioma.
Rottembourg D; O'Gorman CS; Urbach S; Garneau PY; Langer JC; Van Vliet G; Hamilton J; Huot C
J Pediatr Endocrinol Metab; 2009 Sep; 22(9):867-72. PubMed ID: 19960898
[TBL] [Abstract][Full Text] [Related]
15. The development of hypothalamic obesity in craniopharyngioma patients: A risk factor analysis in a well-defined cohort.
van Iersel L; Meijneke RWH; Schouten-van Meeteren AYN; Reneman L; de Win MM; van Trotsenburg ASP; Bisschop PH; Finken MJJ; Vandertop WP; van Furth WR; van Santen HM
Pediatr Blood Cancer; 2018 May; 65(5):e26911. PubMed ID: 29314661
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic update on the treatment of craniopharyngiomas].
Bordallo MA; Ferreira RM; Bulzico DA
Arq Bras Endocrinol Metabol; 2011 Nov; 55(8):520-7. PubMed ID: 22218432
[TBL] [Abstract][Full Text] [Related]
17. A Survey of Patient-Relevant Outcomes in Pediatric Craniopharyngioma: Focus on Hypothalamic Obesity.
Craven M; Crowley JH; Chiang L; Kline C; Malbari F; Hocking MC; McCormack SE
Front Endocrinol (Lausanne); 2022; 13():876770. PubMed ID: 35615720
[TBL] [Abstract][Full Text] [Related]
18. Clinical review: Bariatric surgery following treatment for craniopharyngioma: a systematic review and individual-level data meta-analysis.
Bretault M; Boillot A; Muzard L; Poitou C; Oppert JM; Barsamian C; Gatta B; Müller H; Weismann D; Rottembourg D; Inge T; Veyrie N; Carette C; Czernichow S
J Clin Endocrinol Metab; 2013 Jun; 98(6):2239-46. PubMed ID: 23533238
[TBL] [Abstract][Full Text] [Related]
19. Bariatric Interventions in Craniopharyngioma Patients-Best Choice or Last Option for Treatment of Hypothalamic Obesity?
Müller HL
J Clin Endocrinol Metab; 2022 Jan; 107(1):e426-e428. PubMed ID: 34331765
[No Abstract] [Full Text] [Related]
20. [CranioNet -- an interdisciplinary strategy for craniopharyngioma].
Reschke K; Busse S; Mohnike K; Buchfelder M; Ranke M; Fahlbusch R; Lehnert H
Dtsch Med Wochenschr; 2006 Apr; 131(15):821-4. PubMed ID: 16607603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
